About Cellares
Cellares is a company based in San Francisco (United States) founded in 2019 by Fabian Gerlinghaus and Omar Kurdi. Cellares has raised $682 million across 6 funding rounds from investors including Bristol-Myers Squibb, Koch Disruptive Technologies and DFJ Growth. Cellares operates in a competitive market with competitors including 10X Genomics, Mission Bio, LUMICKS, LevitasBio and Rebus Biosystems, among others.
- Headquarter San Francisco, United States
- Founders Fabian Gerlinghaus, Omar Kurdi
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website cellares.com
- Social LinkedIn
- Total Equity Funding$682M (USD)
in 6 rounds
- Latest Funding Round$50M (USD), Series D
Jun 2026
- InvestorsBristol-Myers Squibb
& 19 more
Funding Insights of Cellares
Cellares has successfully raised a total of $682M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $50 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $682M
- Total Rounds 6
- Last Round Series D — $50M
- First Round $18M
(Aug 2019)
- Investors Count 20
All 6 funding rounds of Cellares with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $50M | Series D | – | – | – |
| Jun 2026 | $20M | Series D | – | – | |
| Jan 2026 | $257M | Series D | – | BlackRock, Eclipse | |
| Aug 2023 | $255M | Series C | – | Koch Disruptive Technologies | |
| Apr 2021 | $82M | Series B | – | Decheng Capital, Eclipse | |
| Aug 2019 | $18M | Series A | – | Eclipse |
20 investors in total: 20 institutional.
Investors in Cellares
Cellares has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include Bristol-Myers Squibb, Koch Disruptive Technologies and DFJ Growth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by the venture capital firm. | 2017 | kochdisruptivetechnologies.com | Wichita, United States | |
Investments are directed toward innovative technology startups by DFJ Growth. | – | dfjgrowth.com | Menlo Park, United States | |
Philanthropic assets are managed by Willett Advisors LLC. | – | willettadvisors.com | New York, United States | |
Early-stage investments are made by Eclipse across multiple sectors. | – | eclipse.vc | Palo Alto, United States | |
Venture capital firm focused on life science and technology sectors | – | decheng.com | Shanghai, China | |
Venture capital firm investing in technology, life sciences, and related sectors. | – | 8vc.com | - | |
Venture capital investments are directed toward life science sectors. | – | skyviewslifescience.com | - | |
- | – | eclipse.capital | - | |
- | – | duquesnefamilyofficellc.tcc.mode | - | |
- | – | edbi.com | - |
Investor details for Cellares
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cellares
85 people are tracked at Cellares (15 in leadership, 8 in board & advisors, 62 in team).
| Name | Role | Group |
|---|---|---|
Fabian Gerlinghaus | Co-Founder & CEO | Leadership |
Omar Kurdi | Co-Founder | Leadership |
Tess Forster | Director Program Management | Leadership |
Wilson Toy | VP, Technology | Leadership |
Laurence Livingston | Chief Financial Officer | Leadership |
Gary Lo | CFO | Leadership |
Richard Bland | Sr. Director Supply Chain | Leadership |
Eric Fulmer | Vice President Of Quality | Leadership |
Ossama Eissa | Chief Operating Officer | Leadership |
Vladimir Azersky | Director, Instrument Software | Leadership |
Aaron Oswald | Director Of Engineering And Facilities | Leadership |
Philip Ip | Senior Director Of IT | Leadership |
Yelena Gertsen | Director, People & Culture | Leadership |
Brian Fors | Director, Software Applications | Leadership |
Matthias Weber | Director Technology Development | Leadership |
Ezekiel J. Emanuel | Advisor | Board & advisors |
Timothy Moore | Advisor | Board & advisors |
Carl June | Advisor | Board & advisors |
Megan Davis | Advisor | Board & advisors |
Rod Rietze | Advisor | Board & advisors |
65 more people are available in the full profile.
Complete people profiles for Cellares
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cellares
3 dated milestones of Cellares across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Cellares is founded.
- Funding First funding round of $18.0M.
- Funding Latest funding round, Series D, of $50.0M.
Competitors of Cellares
Cellares operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, LUMICKS, LevitasBio and Rebus Biosystems, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| lumicks.com | 2014 | Amsterdam, Netherlands | $93.38M | – | Optical tweezers instruments for single-molecule analysis are manufactured. | |
| levitasbio.com | 2017 | San Francisco, United States | $73.77M | – | Single-cell imaging platform developed via magnetic levitation technology. | |
| rebusbio.com | 2006 | Santa Clara, United States | $20M | – | An imaging system for single-cell gene analysis is developed. | |
| atrandi.com | 2016 | Vilnius, Lithuania | $31.01M | – | Microfluidic solutions for life sciences and single-cell analysis are developed. | |
| biolog.com | 1984 | Hayward, United States | $33.62M | 27 | Cell-based phenotyping technologies and assays are provided for microbial analysis. | |
| xcellbio.com | 2012 | San Francisco, United States | $40.9M | 11 | Cell culture analysis devices for cancer research are developed. |
Detailed competitors of Cellares
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Cellares
The website of Cellares (cellares.com) receives about 28.6K visits a month and ranks #1,345,587 among all websites worldwide, #1,741 in Biotechnology and Pharmaceuticals.
- Monthly visits28.6K
▲ 50.9% vs previous month
- Unique visitors5.6K
per month
- Global rank#1,345,587
among all websites
- Category rank#1,741
Health · Biotechnology and Pharmaceuticals
- Bounce rate51%
- Pages per visit2.6
- Average visit2 min 12 sec
- DevicesDesktop 47% · Mobile 53%
Websites whose visitors overlap most with Cellares. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
drugdiscoverytrends.com | drugdiscoverytrends.com | 100% | – | #491,427 | – |
| contractpharma.com | 100% | 67.7K | #631,663 | View details | |
news.bms.com | news.bms.com | 100% | – | #709,486 | – |
pharmtech.com | pharmtech.com | 100% | – | #505,753 | – |
cgtlive.com | cgtlive.com | 68% | – | #1,198,562 | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 8 similar websites and full traffic analytics for Cellares
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 8 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Cellares
Complete news archive for Cellares
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Cellares
10 companies that operate in the same segment as Cellares (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cellares
Cellares was founded in 2019.
Cellares is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Fabian Gerlinghaus is the current CEO of Cellares. They have also founded this company.
Cellares is a funded company, having raised a total of $682M across 6 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Aug 2019.
Cellares was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where medical devices for cell-based therapy are manufactured. The Cell Shuttle platform is provided, integrating technologies for automated, end-to-end manufacturing processes with high throughput. A software suite supporting various cell therapy modalities is also offered to facilitate production workflows.
Cellares's top competitors include 10X Genomics, Mission Bio and LUMICKS.
Cellares has 20 investors. Key investors include Bristol-Myers Squibb, Koch Disruptive Technologies, DFJ Growth, Willett Advisors, and Eclipse.